# A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

> **NCT05869903** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 3127 (actual)

## Conditions studied

- Obesity
- Overweight
- Overweight or Obesity

## Interventions

- **DRUG:** Orforglipron
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05869903
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-05
- **Primary completion:** 2025-07-25
- **Final completion:** 2027-10
- **Target enrollment:** 3127 (ACTUAL)
- **Last updated:** 2025-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05869903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05869903, "A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05869903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*